Back to companies

Sangamo Therapeutics Inc: Overview

Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Sangamo Therapeutics Inc (Sangamo), formerly Sangamo BioSciences Inc, is a biotechnology company that focuses on the research, development, and commercialization of engineered DNA-binding protein Zinc Finger Transcription (ZFPs). Its ZFPs candidates are based on its proprietary gene therapy technologies. It is advancing its pipeline candidates for the treatment of HIV/AIDS, hemophilia A and B, hurler syndrome (MPS I), Fabry disease, Huntington's disease, Alzheimer's disease, and many others. Its ZFPs based products are used in various applications such as human therapeutics, research reagents, pharmaceutical protein production, plant agriculture, cell-line engineering, and production of transgenic animals. Sangamo is headquartered in Brisbane, California, the US.

Headquarters United States of America

Address 7000 Marina Blvd, Brisbane, California, 94005


Telephone 1 510 9706000

No of Employees 431

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange SGMO (NASD)

Revenue (2021) $110.7M -6.3% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -47.3% (2021 vs 2020)

Market Cap* $586.8M

Net Profit Margin (2021) XXX -57.3% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

60+

Pipeline Drugs

Identify which of Sangamo Therapeutics Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

40+

Clinical Trials

Determine Sangamo Therapeutics Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Sangamo Therapeutics Inc’s relevant decision makers and contact details.

13+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Pipeline Sangamo
ZFP Therapeutic Pipeline: Sangamo Therapeutics
SB-525: Better Therapeutics by Design
XXX XXX
XXX XXX
XXX XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Others In January, the company announced Sanofi to transition its rights and obligations related to SAR445136.
2021 Others In December, the company announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136.
2020 Contracts/Agreements In July, the company collaborated with Novartis to develop gene therapies for autism and other brain disorders.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Sangamo Therapeutics Inc Pfizer Inc Merck & Co Inc GSK plc Amgen Inc
Headquarters United States of America United States of America United States of America United Kingdom United States of America
City Brisbane New York Whitehouse Station Brentford Thousand Oaks
State/Province California New York New Jersey - California
No. of Employees 431 79,000 68,000 90,096 24,200
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
H. Stewart Parker Chairman Executive Board 2017 66
Alexander D. Macrae, Ph.D. Chief Executive Officer; President; Director Executive Board 2016 59
Prathyusha Duraibabu Chief Financial Officer; Senior Vice President Senior Management 2021 43
Mark McClung Executive Vice President; Chief Operating Officer Senior Management 2021 59
Whitney Jones Senior Vice President; Chief People Officer Senior Management 2020 -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer